Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy

Cancer

Volumn 101, Issue 4, 2004, Pages 754-760

  Sarosdy, Michael F ^a,b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b South Texas Urology and Urologic Oncology   (United States)

Author keywords

Brachytherapy; Complications; External beam radiation therapy (EBRT); Prostate carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BEAM THERAPY; BLADDER CATHETERIZATION; BRACHYTHERAPY; COLONOSCOPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY CONTROL; RECTUM HEMORRHAGE; TRANSURETHRAL RESECTION; TREATMENT PLANNING; URETER STRICTURE; URINARY DIVERSION; URINE RETENTION;

ADULT; AGED; BRACHYTHERAPY; COHORT STUDIES; COLECTOMY; COLONOSCOPY; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY; RECTAL DISEASES; URINARY CATHETERIZATION; URINARY RETENTION;

EID: 3543092059     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20446     Document Type: Article

References (24)

1. Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 1998;83:989-1001.
2. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839-850.
3. Wallner K, Blasko J, Dattoli MJ, editors. Morbidity. In: Prostate brachytherapy made complicated. Seattle: Smart Medicine Press, 2001:15.1-15.21.
4. Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology. 2000;55:91-96.
5. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:119-124.
6. Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer. 2000;89:2085-2091.
7. Lee WR, McQuellion RP, Case D, deGuzman AF, McCullough DL. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol. 1999;162:403-406.
8. Brandeis IM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. 2000;163:851-857.
9. Fleming ID, Cooper IS, Hemson DE, et al., editors. AICC cancer staging manual, 5th edition. Philadelphia Lippincott-Raven, 1998:219-222.
10. Zelefsky MI, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491-500.
11. Critz FA. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol. 2002;167:1310-1313.
12. Kang SK, Chou RH, Dodge RK, et al. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;53:99-103.
13. Han BH, Wallner KE. Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications. Int J Cancer. 2001;96:372-378.
14. Merrick GS, Butler WM, Dorsey AT, Lief JH, Walbert HL, Blatt HJ. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;43:1021-1027.
15. Hu K, Wallner K. Clinical course of rectal complications following 1-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;41:263-265.
16. Stone NN, Ratnow ER, Stock RG, Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol. 2000;6:123-127.
17. Grann A, Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 1998;40:135-138.
18. Blasko JC, Grimm PD, Sylvester JE, Cavanagh W. The role of external beam radiotherapy with 1-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol. 2000;57:273-278.
19. Abadir R, Ross G, Jr., Weinstein SH. Carcinoma of the prostate treated by pelvic node dissection, iodine-125 seed implant and external irradiation: a study of rectal complications. Clin Radiol. 1984;35:359-361.
20. Merrick GS, Wallner DE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol. 2003;169:1643-1652.
21. Snyder KM, Stock RG, Hons SM, et al. Defining the risk of developing grade 2 proctitis following 1-125 prostate brachytherapy using a rectal dose volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;50:335-341.
22. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal 1-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465-471.
23. Waterman FM, Dicker AP. Probability of late rectal morbidity in 1-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:342-353.
24. Waterman FM, Dicker AP. Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptable low risk of late rectal morbidity. Int J Radiat Oncol Biol Phys. 2003;57:293-299.